• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

类风湿关节炎达标治疗相关影响因素的临床研究

黄玲玲 徐建华 徐胜前 肖会 常玲 刘娜 马芹

黄玲玲, 徐建华, 徐胜前, 肖会, 常玲, 刘娜, 马芹. 类风湿关节炎达标治疗相关影响因素的临床研究[J]. 中华疾病控制杂志, 2016, 20(6): 586-589. doi: 10.16462/j.cnki.zhjbkz.2016.06.012
引用本文: 黄玲玲, 徐建华, 徐胜前, 肖会, 常玲, 刘娜, 马芹. 类风湿关节炎达标治疗相关影响因素的临床研究[J]. 中华疾病控制杂志, 2016, 20(6): 586-589. doi: 10.16462/j.cnki.zhjbkz.2016.06.012
HUANG Ling-ling, XU Jian-hua, XU Sheng-qian, XIAO Hui, CHANG Ling, LIU Na, MA Qin. Treat-to-target of rheumatoid arthritis and potential determinants[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 586-589. doi: 10.16462/j.cnki.zhjbkz.2016.06.012
Citation: HUANG Ling-ling, XU Jian-hua, XU Sheng-qian, XIAO Hui, CHANG Ling, LIU Na, MA Qin. Treat-to-target of rheumatoid arthritis and potential determinants[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2016, 20(6): 586-589. doi: 10.16462/j.cnki.zhjbkz.2016.06.012

类风湿关节炎达标治疗相关影响因素的临床研究

doi: 10.16462/j.cnki.zhjbkz.2016.06.012
基金项目: 

国家自然科学基金青年科学基金(81302587)

详细信息
    作者简介:

    黄玲玲(1989-),女,六安寿县人,在读硕士研究生。主要研究方向:类风湿关节炎。

  • 中图分类号: R181.1;R539.22

Treat-to-target of rheumatoid arthritis and potential determinants

  • 摘要: 目的 调查类风湿关节炎患者(rheumatoid arthritis,RA)达标治疗情况,分析其影响因素,进一步提高RA达标治疗率。方法 选择300例RA患者,详细记录所有患者临床资料,并根据28关节疾病活动性(disease activity score in 28 joints,DAS28)评分分为达标组和未达标组。结果 RA患者中,达标率为36.7%;达标组和未达标组比较:达标组比未达标组患者平均年龄轻、文化程度高、关节肿胀数/关节压痛数少、疼痛程度评分/患者总体评估/医师总体评估(physician global assessment,PGA)低;达标组持续使用致病情缓解抗风湿病药(disease-modifying anti-rheumatic drugs,DMARDs)单药或联合治疗时间≥3个月所占比例高于未达标组;达标患者类风湿因子、红细胞沉降率、C反应蛋白、关节功能分级、生活质量得分低于未达标患者;Logistic回归分析显示:关节功能分级、C反应蛋白、PGA是RA达标治疗独立影响因素。结论 RA患者达标治疗率仍较低,DMARDs正规治疗对达标治疗具有重要作用,关节功能、C反应蛋白、PGA为RA达标治疗独立影响因素。
  • Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update [J]. Ann Rheum Dis, 2014,73:492-509.
    Sokka T, Hetland ML, Mäkinen H, et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries [J]. Arthritis Rheum, 2008,58(9):2642-2651.
    Lutf A, Poil AR, Hammoudeh M. Characteristics of patients With rheumatoid arthritis in Qatar:a cross-sectional study [J]. Int J Rheum Dis, 2014,17(1):63-65.
    Wang GY, Zhang SL, Wang XR, et al. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey [J]. Clin Rheumatol, 2015,34(2):221-230.
    邓雪蓉,周炜,王昱,等. 类风湿关节炎在不同治疗方案下的达标情况及影响因素分析 [J]. 中华风湿病学杂志, 2014,18(6):365-368.
    Katchamart W, Johnson S, Lin HJ, et al. Predictors for remission in rheumatoid Arthritis patients:a systematic review [J]. Arthritis Care Res(Hoboken), 2010,62(8):1128-1143.
    Ellerby N, Mattey DL, Packham J, et al. Obesity and comorbidity are independently associated with a failure to achieve remission in patients with established rheumatoid arthritis [J]. Ann Rheum Dis, 2014,73(11):e74.
    Choy T, Bykerk VP, Boire G, et al. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort [J]. Rheumatology (Oxford), 2014,53(3):482-490.
    Cannon GW, Wang BC, Park GS, et al. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial Experience [J]. Clin Exp Rheumatol, 2013,31(6):919-925.
    van den Broek M, Dirven L, Klarenbeek NB, et al. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study [J]. Ann Rheum Dis, 2012,71(2):245-248.
    Ma MH, Scott IC, Dahanayake C, et al. Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen [J]. J Rheumatol, 2014,41(7):1298-1303.
    Emery P, Hammoudeh M, Fitzgerald O, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis [J]. N Engl J Med, 2014,371(19):1781-1792.
    Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period [J]. Ann Rheum Dis, 2015,74(1):19-26.
    Nakashima Y, Kondo M, Fukuda T, et al. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data [J]. Mod Rheumatol, 2014,24(2):258-264.
    Gossec L, Dougados M, Goupille P, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study [J]. Ann Rheum Dis, 2004,63(6):675-680.
  • 加载中
计量
  • 文章访问数:  472
  • HTML全文浏览量:  73
  • PDF下载量:  34
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-12-04
  • 修回日期:  2016-03-18

目录

    /

    返回文章
    返回